-
-
-
Ki-Suck Jung
President, APSR 2022
Local Congress Committee
Professor, Hallym University College of Medicine -
Jae Jeong Shim
Secretary General, APSR 2022
Local Congress Committee
Professor, Korea University College of Medicine -
Jang-Won Sohn
Vice Secretary General, APSR 2022
Local Congress Committee
Professor, Hanyang University College of Medicine -
Kwang Ha Yoo
Vice Secretary General, APSR 2022
Local Congress Committee
Professor, Konkuk University School of Medicine -
Chin Kook Rhee
Vice Secretary General, APSR 2022
Local Congress Committee
Professor, The Catholic University of Korea College of Medicine
-
Speaker's Highlight
-
-
Don Sin
University of British Columbia, St. Paul Hospital (Canada)
Kenneth R. Chapman
Toronto General Hospital Research Institute (Canada)
-
Parameswaran Nair
McMaster University (Canada)
Carolyn Calfee
UCSF (U.S.A.)
-
Gregory P. Downey
University of Colorado School of Medicine (U.S.A.)
David A. Schwartz
University of Colorado School of Medicine (U.S.A.)
-
Neil Schluger
Tuberculosis Control Branch, California Department of Public Health (U.S.A.)
Nick Kim
Critical Care & Sleep Medicine, University of California San Diego (U.S.A.)
-
Nicola Hananiah
Baylor College of Medicine (U.S.A.)
Jae-Joon Yim
Seoul National University College of Medicine (Republic of Korea)
-
Koichiro Asano
Tokai University School of Medicine (Japan)
Diahn-Warng Perng
Taipei Veterans General Hospital (Taiwan)
-
Konstantinos Kostikas
University of Ioannina (Greece)
Karin Klooster
University Medical Center Groningen (Kingdom of the Netherlands)
-
Corticosteroids and viral clearance in influenza pneumonia
Influenza pneumonia turns a seasonal viral infection into a complicated hospital problem, particularly when bacterial infection, oxygen dependence or acute respiratory distress syndrome develops. The effect of corticosteroids on viral clearance in influenza pneumonia therefore matters, but clearance is only one outcome. Clinicians also need to know whether steroids reduce lung inflammation, improve survival or simply alter how long a virus can be detected.
For respiratory physicians, intensivists and infection specialists attending the APSR and KATRD congress, the practical issue is how to combine evidence about host injury with antiviral treatment. This review separates biological mechanisms, human evidence and bedside decisions in Australia, where timing, drug access and seasonal patterns differ from those described in many overseas cohorts.
Why viral clearance changes clinical decisions
Viral clearance describes the removal of infectious virus from the respiratory tract, not merely the disappearance of symptoms. Influenza can persist in damaged lower-airway tissue after a patient feels better, while some nasopharyngeal swabs become negative despite ongoing severe pneumonia. Viral culture, nucleic acid testing and symptoms therefore measure different aspects of the same illness.
Clearance is clinically relevant because prolonged replication may increase the risk of transmission and continued lung injury. It is not a stand-alone measure of recovery, however. A hospital-acquired infection, bacterial pneumonia or an immune-mediated lung complication can keep a patient unwell long after viable influenza virus has disappeared.
How corticosteroids alter host response
Systemic corticosteroids suppress inflammatory cytokine production, reduce immune-cell recruitment and limit some of the tissue response that contributes to acute lung injury. In severe influenza pneumonia, this dampening of inflammation could reduce oxygen requirements and the risk of progression to acute respiratory distress syndrome.
The same suppression may weaken antiviral defence. Influenza models have shown delayed viral clearance after corticosteroid exposure, particularly when treatment begins early or at a high dose. The effect varies with the virus, steroid dose, duration and severity of the original infection, so laboratory findings cannot be applied directly to every patient.
Inhaled corticosteroids should not be assumed to produce the same systemic effects, although they are not established treatments for shortening influenza illness. Clinicians should also distinguish intentional corticosteroid treatment from its use for another indication, such as chronic obstructive pulmonary disease or another condition complicating the admission.
What the evidence shows
Human evidence is mixed and carries important limitations. Some observational studies of severe influenza, including pandemic H1N1 disease, associated corticosteroids with lower mortality or reduced need for ventilation. Other analyses found no benefit, while early steroid exposure was linked to worse outcomes in selected groups. Patients who receive steroids are often sicker and receive other intensive treatments, making cause and effect difficult to establish.
The strongest biological concern is that corticosteroids may suppress the immune mechanisms needed to eliminate influenza, producing prolonged viral shedding. Yet prolonged detection does not always mean prolonged infectiousness, and it may partly reflect severe disease, sampling from the lower airway or the timing of treatment. Clinical recovery and mortality remain more important outcomes than a single viral-load result.
Randomised evidence specific to influenza pneumonia remains limited, so findings from COVID-19 should not be automatically applied. Steroids are not routinely recommended solely to clear influenza or shorten uncomplicated illness. In severe pneumonia, any decision should consider oxygenation, haemodynamic stability, suspected bacterial co-infection and the need for other supportive treatment.
Australian clinical and seasonal context
Influenza usually peaks from June to September across southern Australia, placing many severe admissions during winter and creating pressure on emergency departments, respiratory wards and intensive care units. In tropical northern Australia, influenza can circulate throughout the year, with heavier activity during the wet season. A recent vaccination does not exclude infection, and unusual symptoms should still prompt testing.
Australian patients commonly move between community and hospital care. A person may consult a general practitioner, attend a public emergency department and receive specialist review from a respiratory registrar or infectious diseases physician. Melbourne’s tertiary hospitals routinely manage severe viral pneumonia, while regional and remote services must often stabilise patients before transfer. Influenza testing should not delay treatment when the diagnosis is strongly suspected.
For eligible patients, oseltamivir is available through the Pharmaceutical Benefits Scheme under current restrictions, while private prescriptions and hospital formularies determine access in other circumstances. On Australian wards, teams often frame the choice plainly: antivirals target the virus, steroids may dampen harmful inflammation, and neither replaces oxygen therapy, physiotherapy or management of secondary infection.
Recommendations for respiratory teams
Clear local guidance is more useful than a blanket rule for or against corticosteroids. The following recommendations support decisions that can be applied during admission:
- Start appropriate influenza antiviral therapy promptly when the diagnosis is credible, rather than waiting for prolonged viral clearance.
- Document whether corticosteroids are being used for lung injury, another indication or an unclear reason, including dose and stop date.
- Interpret viral tests alongside symptoms, imaging and oxygen needs, using lower-airway samples when upper-airway results do not match the clinical picture.
- Review bacterial co-infection and unnecessary antimicrobial exposure each day, because complications may drive prolonged admission independently of influenza.
Senior respiratory, infectious diseases and intensive care input should be sought early when there is severe hypoxaemia, rapid progression, shock or substantial immunosuppression. Decisions should be reassessed as the diagnosis and respiratory trajectory become clearer rather than continuing automatically because a steroid order was placed at admission.
Building a reliable response pathway
A dependable pathway begins before the next seasonal surge. Hospitals can align testing, antiviral access, steroid governance and documentation across emergency, respiratory and intensive care services. Audit data should distinguish confirmed influenza from clinical suspicion and record outcomes such as ventilation, mortality, length of stay and duration of viral detection.
The APSR and KATRD program offers clinicians a valuable setting for comparing these pathways with colleagues from other health systems. Attendees extending a stay in northern Australia after the Melbourne congress may find a banana tree guide useful when comparing tropical destinations and planning travel around the meeting.
Within 30 days, each respiratory and intensive care team should review one patient pathway, name the clinician responsible for steroid decisions, and record clear criteria for antiviral timing and reassessment.
Richard Russell
Nuffield Department of Clinical Medicine, University of Oxford (United Kingdom)
-
Mona Bafadhel
King’s College London (United Kingdom)
David Jackson
Guy’s and St Thomas’ Hospital, King’s College London (United Kingdom)
-
James Chalmers
University of Dundee (United Kingdom)
David Price
University of Aberdeen (United Kingdom)
-